Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naive SB5 Observational Cohorts

Autor: Laura Kirckpatrick, Caitlin S Rees, Lauranne A A P Derikx, Claire O'Hare, Charlie W. Lees, Nikolas Plevris, Philip Jenkinson, S Siakavellas, Nathan Constantine-Cooke, Laura Lucaciu, Gareth-Rhys Jones, Heather W Dolby, Lynne M Merchant, Ian D. Arnott, Colin L. Noble, Shanna Su, Mathew Lyons

Publikováno v: Journal of Crohn's and Colitis, 15, 2011-2021
Journal of Crohn's & Colitis
Journal of Crohn's and Colitis, 15, 12, pp. 2011-2021

Background and Aims Multiple adalimumab [ADA] biosimilars are now approved for use in inflammatory bowel disease [IBD]; however, effectiveness and safety data remain scarce. We aimed to investigate long-term outcomes of the ADA biosimilar SB5 in IBD

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8c18e73aade15417255084528433aa1
https://hdl.handle.net/2066/244226